Targeted drug delivery platform technology applicable to a range of solid tumors. Our initial target is glioblastoma,a brain tumor with a five-year survival rate of only 3% We deliver directly to the tumor cell a payload that is lethal to the tumor but has little effect on healthy cells.



View Details...